Previously, the MD Anderson- Korea University research team also published the genetic classification system for liver cancer in Hepatology.
Gastric cancer tends to have genetic and clinical diversity. The research team analyzed the gene classification system for 8 gastric cancers that was published in the past and derived the result of 6 Consensus Genomic Subtypes (CGSs). This system classified gastric cancers from CGS1 to CGS6 depending on different gene expression patterns.
Each subtype had different characteristics and CGS1 showed the worst prognostic features. It had very high stem cell properties and low genetic modification. However, the analysis confirmed that CGS1 responded well to immunotherapy and treatments targeting IGF1R could be effective. CGS2 was enriched in typical epithelial cell gene expression. CGS3 and CGS4 showed high cloning number variation and had low responses to immunotherapy.
Nevertheless, CGS3 had a characteristic of HER2 gene activation and CGS4 had a characteristic of SALL4 gene activation. The team analyzed that treatments targeting those features would be effective. CGS5 had high mutation burden, which is a characteristic of microsatellite instability in tumors, and showed moderate response to immunotherapy. CGS6 was mostly positive for infectious mononucleosis (Epstein Barr) virus and had very high methylation levels. It showed a high response to immunotherapy.
The research team not only classified genetics of gastric cancer, but also estimated the potential response rates of standard and experimental treatments (chemoradiotherapy, immunotherapy, etc.) for each subtype through systematic analysis of genome and proteome data. As a result, the CGS3 subtype showed especially great benefits in anticancer radiotherapy due to its iron-dependent cell death due to high level lipid peroxidation. Research suggested potential treatment subjects for each subtype.
Professor Sun Young Yim of the Division of Gastroenterology and Hepatology, one of the lead authors of this study, said, “Although the mortality rate of gastric cancer is decreasing due to the implementation of new therapies, it still is one of the major causes of death for cancer patients. We believe that this research is going to lay the foundation for personalized gastric cancer treatments.”
More information:
Yun Seong Jeong et al, Clinically conserved genomic subtypes of gastric adenocarcinoma, Molecular Cancer (2023). DOI: 10.1186/s12943-023-01796-w
Provided by
Korea University College of Medicine
Citation:
A new gene classification system for gastric cancer (2023, November 6)
retrieved 6 November 2023
from https://medicalxpress.com/news/2023-11-gene-classification-gastric-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.